This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
Diamyd Medical AB (publ)
Q42024
10/9/2024
Linus Svensson
Moderator, GOV
Hello everyone, my name is Linus Svensson from GOV and we would like to welcome you all to this quarter's update together with Diamyd Medical. The book house communiqué was released this morning, I hope everyone had a chance to look through it and read a little bit. And just like the latest report we did here with GOV, we have with us the company's CEO Ulf Hanelius who will tell us a little about the company's status and What has happened in the last quarter, there have been several positive news related to the development of both the company as a large and phase three. And just about a week later, it turned out to be a success with Teo 3, which gave about 50 million in the cash register. And of course it's good to send questions via chat at any time during the presentation, then we take them up after Ulf has passed the quarter. So I think that with that said, we leave the floor to you Ulf, so have a good one.
Ulf Hanelius
CEO, Diamyd Medical
Tusen tack och välkomna alla, 32 stycken hittills, det är fantastiskt. Ska vi säga, jag börjar med att dela min powerpoint här. Och det syns bra.
Linus Svensson
Moderator, GOV
Det syns bra.
You're reading a preview of the DMYD-B.ST Q4 2024 earnings call.
Free account.
Disclaimer